ATE409027T1 - Magensaftresistente salze von ketosäuren und aminosäuren und ihre verwendung zur herstellung von medikamenten - Google Patents

Magensaftresistente salze von ketosäuren und aminosäuren und ihre verwendung zur herstellung von medikamenten

Info

Publication number
ATE409027T1
ATE409027T1 AT02757738T AT02757738T ATE409027T1 AT E409027 T1 ATE409027 T1 AT E409027T1 AT 02757738 T AT02757738 T AT 02757738T AT 02757738 T AT02757738 T AT 02757738T AT E409027 T1 ATE409027 T1 AT E409027T1
Authority
AT
Austria
Prior art keywords
medications
production
acids
amino acids
juice resistant
Prior art date
Application number
AT02757738T
Other languages
English (en)
Inventor
Thierry Bouyssou
Serge Biosa
Christian Jeanpetit
Daniel Kilhoffer
Peillet-Feuillet Eliane Le
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of ATE409027T1 publication Critical patent/ATE409027T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
AT02757738T 2001-03-29 2002-03-27 Magensaftresistente salze von ketosäuren und aminosäuren und ihre verwendung zur herstellung von medikamenten ATE409027T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0104259A FR2822704B1 (fr) 2001-03-29 2001-03-29 Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments

Publications (1)

Publication Number Publication Date
ATE409027T1 true ATE409027T1 (de) 2008-10-15

Family

ID=8861695

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02757738T ATE409027T1 (de) 2001-03-29 2002-03-27 Magensaftresistente salze von ketosäuren und aminosäuren und ihre verwendung zur herstellung von medikamenten

Country Status (15)

Country Link
US (1) US20040127413A1 (de)
EP (1) EP1372617B1 (de)
AT (1) ATE409027T1 (de)
AU (1) AU2002308031A1 (de)
CA (1) CA2442691A1 (de)
CZ (1) CZ20032488A3 (de)
DE (1) DE60229044D1 (de)
DZ (1) DZ3512A1 (de)
EA (1) EA007010B1 (de)
FR (1) FR2822704B1 (de)
HU (1) HUP0303628A2 (de)
MA (1) MA26009A1 (de)
PL (1) PL365213A1 (de)
TN (1) TNSN03075A1 (de)
WO (1) WO2002078676A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069236A1 (ja) * 2003-02-06 2004-08-19 Otsuka Pharmaceutical Factory, Inc. 周術期血糖値上昇抑制剤
EP1638546A1 (de) * 2003-07-01 2006-03-29 Essentys AB Verwendung von alpha-ketoglutarsäure zur behandlung von unterernährung oder hohem plasma-blutzucker
PL369552A1 (pl) * 2004-08-12 2006-02-20 Sgp & Sons Ab Preparat farmaceutyczny lub/i żywieniowy lub/i laboratoryjny wzmagający, wspomagający funkcjonowanie komórek nerwowych i układu nerwowego oraz zastosowanie preparatu farmaceutycznego lub/i żywieniowego w procesie ochrony funkcji układu nerwowego oraz zastosowanie preparatu do ochrony wzrostu stymulacji namnażania i zapobiegania apoptozie komórek nerwowych
PL226695B1 (pl) * 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
US20100303901A1 (en) * 2007-04-26 2010-12-02 Eyal Shimoni Oral delivery of proteins and peptides
CN104825433A (zh) * 2007-07-03 2015-08-12 达努塔·克鲁谢夫斯卡 α-酮戊二酸的新医药用途
FR2953719A1 (fr) 2009-12-10 2011-06-17 Luc Cynober Nouvelles applications therapeutiques d'un complexe d'alpha-cetoglutarate et d'ornithine
US20150025147A1 (en) * 2012-03-02 2015-01-22 Kyowa Hakko Bio Co., Ltd Enhancer for eating activity and/or gastrointestinal activity
ITBO20120226A1 (it) 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
WO2016003854A1 (en) * 2014-06-30 2016-01-07 The Regents Of The University Of California Ketobutyrate compounds and compositions for treating age-related symptoms and diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3441650A (en) * 1965-07-23 1969-04-29 Lab Jacques Logeais Sa Therapy of ammonical intoxications by di-l-ornithine alpha-ketoglutarate
FR2618331B1 (fr) * 1987-07-23 1991-10-04 Synthelabo Compositions pharmaceutiques utiles pour le traitement de l'uremie
US4957938A (en) * 1989-06-21 1990-09-18 Abbott Laboratories Nutritional formulation for the treatment of renal disease
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5817329A (en) * 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
FR2775901B1 (fr) * 1998-03-13 2000-07-21 Logeais Labor Jacques Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients

Also Published As

Publication number Publication date
WO2002078676A2 (fr) 2002-10-10
DE60229044D1 (de) 2008-11-06
CZ20032488A3 (cs) 2004-10-13
FR2822704B1 (fr) 2005-02-18
FR2822704A1 (fr) 2002-10-04
EP1372617B1 (de) 2008-09-24
WO2002078676A3 (fr) 2003-01-16
AU2002308031A1 (en) 2002-10-15
HUP0303628A2 (hu) 2004-03-01
EA007010B1 (ru) 2006-06-30
EA200300940A1 (ru) 2004-04-29
TNSN03075A1 (fr) 2005-12-23
PL365213A1 (en) 2004-12-27
MA26009A1 (fr) 2003-12-31
EP1372617A2 (de) 2004-01-02
DZ3512A1 (fr) 2002-10-10
CA2442691A1 (en) 2002-10-10
US20040127413A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
DE60010702D1 (de) Behandlung von titanerz zur herstellung von titandioxidpigmenten
DE60110497D1 (de) Verfahren zur Herstellung von Acrylsäure
WO2003039454A8 (en) Beta-secretase inhibitors and methods of use
DE60222644D1 (de) Prozess zur herstellung von transparenten formteilen
ATE401309T1 (de) Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen
DE60321625D1 (de) Verfahren zur Herstellung von Acrylsäure
DE60200401D1 (de) Verfahren zur Herstellung von aromatischen Karbonsäuren
ATE409027T1 (de) Magensaftresistente salze von ketosäuren und aminosäuren und ihre verwendung zur herstellung von medikamenten
DE60201498D1 (de) Verbesserter prozess zur herstellung von carbapenemen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60005870D1 (de) Verfahren zur Herstellung von Acrylsäure
DE60038560D1 (de) Verfahren zur fermentativen Herstellung von L-Arginin
ATE218335T1 (de) Salze der ketosäuren und amine sowie ihre verwendung zur herstellung von medikamenten
DE60321626D1 (de) Verfahren zur Herstellung von Acrylsäure
DE69912773D1 (de) Nicht hydratisiertes gabapentin polymorph, herstellungsprozess und verwendung zur herstellung von gabapentin pharmazeutischer reinheit.
DE60315741D1 (de) Verfahren zur Herstellung von Acrylsäure
DE60220554D1 (de) Mikrowelleninduzierter prozess zur herstellung von substituierten 4-vinylphenolen
DE60239085D1 (de) Prozess zur Herstellung von E-Caprolactam
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE60216135D1 (de) Prozess zur herstellung von organischen hydroperoxiden
DE60012337D1 (de) Verfahren zur herstellung von fluorcarbonsäureanyhydriden
DE50211253D1 (de) Verfahren zur Herstellung von Makrokapseln
DE60322416D1 (de) Methode zur herstellung von indan-1,3-dicarbonsäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties